GLP-1 Receptor Agonists in Diabetic Kidney Disease : From Physiology to Clinical Outcomes
Rojano-Toimil, Alba (Hospital Universitari Vall d'Hebron)
Ciudin, Andreea (Hospital Universitari Vall d'Hebron. Institut de Recerca)

Data:	2021
Resum:	Diabetic kidney disease (DKD) is one of the most common complications in type 2 diabetes mellitus (T2D) and a major cause of morbidity and mortality in diabetes. Despite the widespread use of nephroprotective treatment of T2D, the incidence of DKD is increasing, and it is expected to become the fifth cause of death worldwide within 20 years. Previous studies have demonstrated that GLP-1 receptor agonists (GLP-1 RA) have improved macrovascular and microvascular outcomes independent of glycemic differences, including DKD. GLP-1Ras' improvement on kidney physiology is mediated by natriuresis, reduction in hyperfiltration and renin-angiotensin-aldosterone system (RAAS) activity and anti-inflammatory properties. These findings translate into improved clinical outcomes such as an enhanced urine albumin-to-creatinine ratio (UACR) and a reduction in renal impairment and the need for renal replacement therapies (RRT). In this article, we review the role of GLP-1RAs on the mechanisms and effect in DKD and their clinical efficacy.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Diabetic kidney disease ; GLP-1 receptor agonists
Publicat a:	Journal of clinical medicine, Vol. 10 (august 2021) , ISSN 2077-0383

DOI: 10.3390/jcm10173955
PMID: 34501404

13 p, 301.6 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats